Abstract: A visual field testing method is a visual field testing method of testing a visual field range divided into at least a first partial area and a second partial area, the method including: a step of measuring sensitivities of a plural first test points that are included in the first partial area: and a step of performing a process of estimating sensitivities of a plural second test points that are included in the first partial area and are test points other than the first test points, by using the sensitivities of the plural first test points.

Abstract: The gas-liquid separator comprises: a swirl structure that causes a gas heading from upstream to downstream to swirl about a flow axis heading from upstream to downstream; a separation structure that discharges outward liquid components contained in the gas passing through the swirl structure; and a deflection structure that is provided downstream of the swirl structure and deflects the gas that has passed through the swirl structure. The deflection structure is provided with: a narrowing core portion that has a three-dimensional shape which narrows from upstream to downstream; and deflecting fins that are provided to the side surface of the narrowing core portion and deflect the gas in the opposite direction to the swirling direction resulting from the swirl structure.

Abstract: A first server and a second server use a virtual address to mount the storage synchronous area in a storage by the NFS. The first server obtains a snapshot of memory content of a virtual system operated as an active system and transmits the snapshot to the second server. The first server replicates content of the storage synchronous area in the storage to a storage synchronous area in a storage. When a failure occurs in the first server, the second server sets a virtual address to the storage and uses the virtual address to mount the storage synchronous area in the storage by NFS. The second server uses the snapshot received from the first server to execute the application on the virtual system.

Abstract: The present invention provides hyaluronic acid derivatives including one or more of each of repeating units represented by the formulae (Ia), (Ib), and (Ic) in which certain cationic sites, certain hydrophobic sites, and certain hydrophilic sites have been introduced. In addition, the present invention provides complexes of the hyaluronic acid derivatives with a drug and pharmaceutical compositions including the hyaluronic acid derivatives, in particular, complexes of the hyaluronic acid derivatives with a drug.

Abstract: A first server and a second server use a virtual address to mount the storage synchronous area in a storage by the NFS. The first server obtains a snapshot of memory content of a virtual system operated as an active system and transmits the snapshot to the second server. The first server replicates content of the storage synchronous area in the storage to a storage synchronous area in a storage. When a failure occurs in the first server, the second server sets a virtual address to the storage and uses the virtual address to mount the storage synchronous area in the storage by NFS. The second server uses the snapshot received from the first server to execute the application on the virtual system.

Abstract: The present invention provides hyaluronic acid derivatives into which a certain cationic group and a certain hydrophobic group are introduced, the hyaluronic acid derivatives including one or more repeating units represented by the formula (Ia) and one or more repeating units represented by the formula (Ib).

Abstract: The present invention provides hyaluronic acid derivatives including one or more of each of repeating units represented by the formulae (Ia), (Ib), and (Ic) in which certain cationic sites, certain hydrophobic sites, and certain hydrophilic sites have been introduced. In addition, the present invention provides complexes of the hyaluronic acid derivatives with a drug and pharmaceutical compositions including the hyaluronic acid derivatives, in particular, complexes of the hyaluronic acid derivatives with a drug.

Abstract: A binding method of a perfect-bound booklet includes the steps of folding each leaf of sheets forming a body to obtain multiple signatures; pressing creased parts of the multiple signatures in a thickness direction thereof; jogging a one-book bundle formed of a predetermined number of signatures forming a body, a front cover, and a back cover, or a multi-book bundle formed by stacking a plurality of one-book bundles on top of one another; applying a first adhesive that remains flexible upon curing, in a layer in a middle area 5 to 10 millimeters from both top and bottom ends of a rear face of the one-book bundle or the multi-book bundle; applying a second adhesive on the entire rear face; and drying and curing the second adhesive for a predetermined drying time.

Abstract: A binding method of a perfect-bound booklet includes the steps of folding each leaf of sheets forming a body to obtain multiple signatures; pressing creased parts of the multiple signatures in a thickness direction thereof; jogging a one-book bundle formed of a predetermined number of signatures forming a body, a front cover, and a back cover, or a multi-book bundle formed by stacking a plurality of one-book bundles on top of one another; applying a first adhesive that becomes flexible by its curing, in a layer in a middle area 5 to 10 millimeters from both top and bottom ends of a rear face of the one-book bundle or the multi-book bundle; applying a second adhesive on the entire rear face; and drying and curing the second adhesive for a predetermined drying time.

Abstract: The present invention provides hyaluronic acid derivatives into which a certain cationic group and a certain hydrophobic group are introduced, the hyaluronic acid derivatives including one or more repeating units represented by the formula (Ia) and one or more repeating units represented by the formula (Ib).

Abstract: The maintenance management device 3 includes an error status diagnosis unit 11, a grace period estimation unit 14, a maintenance cost estimation unit 15, and a screen display unit 17. When the error status diagnosis unit 11 has diagnosed the occurrence of an anomaly, the grace period estimation unit 14 estimates a first grace period leading up to the occurrence of a failure. The maintenance cost estimation unit 15 estimates the cost of corrective maintenance incurred when the failure occurs after the elapse of the first grace period. The screen display unit 17 displays a combination of the first grace period and the cost of corrective maintenance. Alternatively, the grace period estimation unit 14 estimates a second grace period over which preventive maintenance may be postponed without a failure.

Abstract: A diagnostic system for a work machine includes a data storage device (210) in which sensor information (A) input from a sensor (101A) that senses an oil property of oil used for operation of the work machine and an abnormality degree determination value defined for each kind of the sensor information (A) are stored, and an arithmetic processing device (104) that executes first processing of discriminating the degree of abnormality level of the oil based on the sensor information (A) and the abnormality degree determination value, second processing of determining whether or not necessity to carry out oil analysis involving oil extraction exists based on the degree of abnormality level of the oil discriminated in the first processing, and third processing of outputting information indicating that the oil analysis is necessary to other terminal if it is determined that the oil analysis is necessary in the second processing.

Abstract: A diagnostic system for a work machine includes a data storage device (210) in which sensor information (A) input from a sensor (101A) that senses an oil property of oil used for operation of the work machine and an abnormality degree determination value defined for each kind of the sensor information (A) are stored, and an arithmetic processing device (104) that executes first processing of discriminating the degree of abnormality level of the oil based on the sensor information (A) and the abnormality degree determination value, second processing of determining whether or not necessity to carry out oil analysis involving oil extraction exists based on the degree of abnormality level of the oil discriminated in the first processing, and third processing of outputting information indicating that the oil analysis is necessary to other terminal if it is determined that the oil analysis is necessary in the second processing.

Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.

Abstract: The maintenance management device 3 includes an error status diagnosis unit 11, a grace period estimation unit 14, a maintenance cost estimation unit 15, and a screen display unit 17. When the error status diagnosis unit 11 has diagnosed the occurrence of an anomaly, the grace period estimation unit 14 estimates a first grace period leading up to the occurrence of a failure. The maintenance cost estimation unit 15 estimates the cost of corrective maintenance incurred when the failure occurs after the elapse of the first grace period. The screen display unit 17 displays a combination of the first grace period and the cost of corrective maintenance. Alternatively, the grace period estimation unit 14 estimates a second grace period over which preventive maintenance may be postponed without a failure.

Abstract: To advance a dump truck quickly and smoothly to a position where target loading work will be performed relative to an excavating machine, the dump truck is placed in loading target position relative to the excavating machine. Geographic position is detected from GPS satellites of a GPS receiver of the dump truck. The position and direction of the geographic position is transmitted to the excavating machine as a target position image. The target position image and an approach route leading to the position are displayed on a dump truck display when the truck thereafter approaches the position. The dump truck thereafter approaches the position, and the truck is driven so that a current position image advances along the approach route to the target position image, whereby the dump truck is placed in the set loading image target position.

Abstract: To advance a dump truck quickly and smoothly to a position where target loading work will be performed relative to an excavating machine, the dump truck is placed in loading target position relative to the excavating machine. Geographic position is detected from GPS satellites of a GPS receiver of the dump truck. The position and direction of the geographic position is transmitted to the excavating machine as a target position image. The target position image and an approach route leading to the position are displayed on a dump truck display when the truck thereafter approaches the position. The dump truck thereafter approaches the position, and the truck is driven so that a current position image advances along the approach route to the target position image, whereby the dump truck is placed in the set loading image target position.

Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.

Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.

Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.